7月13日 - ** BMO资本市场将艾伯维（ABBV.N）的目标股价从258美元上调至300美元，并维持“跑赢大盘”评级
** 该机构表示，尽管新上市的疗法带来了竞争压力，但重磅免疫类药物Skyrizi和Rinvoq的持续强劲表现，支撑了其对这家制药公司的乐观看法
** 预计Skyrizi的销售额将保持韧性，理由包括其疗效显著、已获批用于治疗银屑病关节炎以及给药频率较低
** 新目标价较该股上一交易日收盘价有约21%的上行空间
** 关于医美业务，BMO表示，宏观经济压力以及消费者偏好转向更自然的外观，继续对真皮填充剂品牌Juvederm构成压力
** 对Botox Cosmetic持更乐观态度，理由包括季节性需求、退税金额增加以及GLP-1减肥药使用量的提升
** 预计艾伯维（AbbVie）将公布第二季度营收168.3亿美元，略高于市场共识；但每股收益为3.59美元，因近期披露的研发相关费用而低于市场共识
** 33家券商中有26家给予该股“买入”或更高评级，7家给予“持有”评级；目标价中位数为263美元——LSEG数据
** 截至上一交易日收盘，该股年内累计上涨8.6%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.